Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/58996
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL
Author: Tojo, A.
Usuki, K.
Urabe, A.
Maeda, Y.
Kobayashi, Y.
Jinnai, I.
Ohyashiki, K.
Nishimura, M.
Kawaguchi, T.
Tanaka, H.
Miyamura, K.
Miyazaki, Y.
Hughes, T.
Branford, S.
Okamoto, S.
Ishikawa, J.
Okada, M.
Usui, N.
Tanii, H.
Amagasaki, T.
et al.
Citation: International Journal of Hematology, 2009; 89(5):679-688
Publisher: Garden Jennings Publ Co Ltd
Issue Date: 2009
ISSN: 0925-5710
1865-3774
Statement of
Responsibility: 
Arinobu Tojo... Timothy Hughes... Susan Branford... et al.
Abstract: Nilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety, and pharmacokinetics of nilotinib in Japanese patients with imatinibresistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or relapsed/ refractory Ph+ acute lymphoblastic leukemia (ALL). A total of 34 patients were evaluated in this analysis and had a median duration of drug exposure of 293 (range 13–615) days. All 6 CML-CP patients without complete hematologic response (CHR) at baseline rapidly achieved CHR. A major cytogenetic response was achieved in 94% of patients with CML-CP, including a complete cytogenetic response in 69%. A major molecular response was achieved by 56%. These responses were also observed in patients with CML in advanced stages and Ph+ ALL. Non-hematologic adverse events were mostly mild to moderate. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 50 and 28% of patients, respectively. Overall, the results of this study suggest that nilotinib induced significant responses inimatinib-resistant or -intolerant patients with CML-CP and CML in advanced stages and Ph+ ALL. The results of this study confirmed the efficacy and safety of nilotinib in Japanese patients.
Keywords: Nilotinib; CML; BCR-ABL; Imatinib resistant; Ph+ ALL
Rights: Copyright The Japanese Society of Hematology 2009
RMID: 0020090762
DOI: 10.1007/s12185-009-0327-0
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.